Defective interfering particle

Defection

DIPs are a naturally occurring phenomenon that can be recreated under experimental conditions in the lab and can also be synthesized for experimental use. They are spontaneously produced by error-prone viral replication, something particularly prevalent in RNA viruses over DNA viruses due to the enzyme used (replicase, or RNA-dependent RNA polymerase.) DIP genomes typically retain the terminal sequences needed for recognition by viral polymerases, and sequences for packaging of their genome into new particles, but little else. The size of the genomic deletion event can vary greatly, with one such example in a DIP derived from rabies virus exhibiting a 6.1 kb deletion. In another example, the size of several DI-DNA plant virus genomes varied from one tenth of the size of the original genome to one half.

Interference

The particles are considered interfering when they affect the function of the parent virus through competitive inhibition

This interfering nature is becoming more and more important for research on virus therapies. It is thought that because of their specificity, DIPs will be targeted to sites of infection. In one example, scientists have used DIPs to create "protecting viruses", which attenuated the pathogenicity of an influenza A infection in mice, through inducing an interferon response, to a point that it was no longer lethal. For SARS-CoV-2, the first synthetic DIPs were made in 2020 and the interference effect was used to generate therapeutic interfering particles (TIPs) that reduced pathogenesis and protected hamsters from serious disease.

Pathogenesis

DIPs have been shown to play a role in pathogenesis of certain viruses. One study demonstrates the relationship between a pathogen and its defective variant, showing how regulation of DI production allowed the virus to attenuate its own infectious replication, decreasing viral load and thus enhance its parasitic efficiency by preventing the host from dying too fast. This also provides the virus with more time to spread and infect new hosts. DIP generation is regulated within viruses: the Coronavirus SL-III cis-acting replication element (shown in the image) is a higher-order genomic structure implicated in the mediation of DIP production in bovine coronavirus, with apparent homologs detected in other coronavirus groups.

Types of defective RNA genomes

1. Deletions defections are when a fragment of the template is skipped. Examples of this type of defection can be found in tomato spotted wilt virus and Flock House virus.
2. Snapbacks defections are when replicase transcribes part of one strand then uses this new strand as a template. The result of this can produce a hairpin. Snapback defections have been observed in vesicular stomatitis virus.
3. Panhandle defections are when the polymerase carries a partially made strand and then switches back to transcribe the 5' end, forming the panhandle shape. Panhandle defections are found in influenza viruses.
4. Compound defections are when both a deletion and snapback defection happens together.
5. Mosaic or complex DI genome, in which the various regions may come from the same helper virus genome but in the wrong order; from different helper genome segments, or could include segments of host RNA. Duplications may also occur.

Research

Research has been conducted by virologists to learn more about the interference in infection of host cells and how DI genomes could potentially work as immunostimulatory antiviral agents. a purely theoretical concept until recently. A 2014 article describes the pre-clinical work to test the immunostimulatory effectiveness of a DIP against influenza viruses by inducing the innate antiviral immune responses (i.e., interferon). Subsequent work tested the pre-clinical efficacy of TIPs against HIV and SARS-CoV-2. DI-RNAs have also been found to aid in the infection of fungi via viruses of the family Partitiviridae for the first time, which makes room for more interdisciplinary work.

Several tools as ViReMa and DI-tector have been developed to help to detect defective viral genomes in next-generation sequencing data and high-throughput approaches, such as random-deletion library sequencing (RanDeL-Seq), allow rational mapping of the viral genetic elements that are required for DI-particle propagation.

References

References

1. (June 2003). "Stem-loop III in the 5' untranslated region is a cis-acting element in bovine coronavirus defective interfering RNA replication". Journal of Virology.
2. (January 1994). "Nonhomologous RNA recombination in tombusviruses: generation and evolution of defective interfering RNAs by stepwise deletions". Journal of Virology.
3. (January 2010). "Defective interfering viruses and their potential as antiviral agents". Reviews in Medical Virology.
4. (November 1999). "Nonreplicative RNA recombination in poliovirus". Journal of Virology.
5. (December 2009). "Defective Interfering RNAs: Foes of Viruses and Friends of Virologists". Viruses.
6. (October 1988). "Primary structure and translation of a defective interfering RNA of murine coronavirus". Virology.
7. (2011). "Oxford Textbook of Zoonoses: Biology, Clinical Practice, and Public Health Control". OUP Oxford.
8. (October 1952). "Studies on the sedimentation of influenza virus". Archiv für die Gesamte Virusforschung.
9. (September 1964). "A possible morphologic basis for the autointerference phenomenon in vesicular stomatitis virus". Virology.
10. (September 2015). "Immunostimulatory Defective Viral Genomes from Respiratory Syncytial Virus Promote a Strong Innate Antiviral Response during Infection in Mice and Humans". PLOS Pathogens.
11. (2012). "Cloned defective interfering influenza virus protects ferrets from pandemic 2009 influenza A virus and allows protective immunity to be established". PLOS ONE.
12. (July 2013). "Sequence analysis of in vivo defective interfering-like RNA of influenza A H1N1 pandemic virus". Journal of Virology.
13. (November 2016). "Experimental piscine alphavirus RNA recombination in vivo yields both viable virus and defective viral RNA". Scientific Reports.
14. (October 1988). "Biased hypermutation and other genetic changes in defective measles viruses in human brain infections". Cell.
15. (December 1990). "Analysis of efficiently packaged defective interfering RNAs of murine coronavirus: localization of a possible RNA-packaging signal". Journal of Virology.
16. (November 1979). "Characterization of a new isolate of poliovirus defective interfering particles". Cell.
17. (April 2009). "Multiple-hit inhibition of infection by defective interfering particles". The Journal of General Virology.
18. (February 2013). "Effects of defective interfering RNA on symptom induction by, and replication of, a novel partitivirus from a phytopathogenic fungus, Rosellinia necatrix". Journal of Virology.
19. (2015). "Introduction to Modern Virology". John Wiley & Sons.
20. (October 1992). "Defective interfering L RNA segments of tomato spotted wilt virus retain both virus genome termini and have extensive internal deletions". The Journal of General Virology.
21. (October 1991). "An L (polymerase)-deficient rabies virus defective interfering particle RNA is replicated and transcribed by heterologous helper virus L proteins". Virology.
22. (2006). "Defective Interfering Dnas of Plant Viruses.". Critical Reviews in Plant Sciences.
23. (December 2021). "Identification of a therapeutic interfering particle-A single-dose SARS-CoV-2 antiviral intervention with a high barrier to resistance". Cell.
24. (September 2003). "Theoretical design of a gene therapy to prevent AIDS but not human immunodeficiency virus type 1 infection". Journal of Virology.
25. (September 2010). "Population dynamics of an RNA virus and its defective interfering particles in passage cultures". Virology Journal.
26. (March 2011). "A novel broad-spectrum treatment for respiratory virus infections: influenza-based defective interfering virus provides protection against pneumovirus infection in vivo". Vaccine.
27. (1 July 2021). "A Synthetic Defective Interfering SARS-CoV-2". PeerJ.
28. (December 2021). "Interfering viral-like particles inhibit SARS-CoV-2 replication". Nature Reviews. Drug Discovery.
29. (June 2013). "Deciphering the mechanism of defective interfering RNA (DI RNA) biogenesis reveals that a viral protein and the DI RNA act antagonistically in virus infection". Journal of Virology.
30. (April 1970). "Defective viral particles and viral disease processes". Nature.
31. (May 2017). "Parallel ClickSeq and Nanopore sequencing elucidates the rapid evolution of defective-interfering RNAs in Flock House virus". PLOS Pathogens.
32. (February 1981). "Structure and origin of a snapback defective interfering particle RNA of vesicular stomatitis virus". Journal of Virology.
33. (June 1994). "The influenza virus panhandle is involved in the initiation of transcription". Journal of Virology.
34. (March 2011). "Autonomous targeting of infectious superspreaders using engineered transmissible therapies". PLOS Computational Biology.
35. Gladstone Institutes. "A New Class of Antiviral Therapy Could Treat COVID-19".
36. (May 2014). "Defective interfering influenza virus RNAs: time to reevaluate their clinical potential as broad-spectrum antivirals?". Journal of Virology.
37. (2019-10-30). "Discovery and Engineering of a Therapeutic Interfering Particle (TIP): a combination self-renewing antiviral".
38. (January 2014). "Discovery of functional genomic motifs in viruses with ViReMa-a Virus Recombination Mapper-for analysis of next-generation sequencing data". Nucleic Acids Research.
39. (October 2018). "''DI-tector'': defective interfering viral genomes' detector for next-generation sequencing data". RNA.
40. (January 2021). "RanDeL-Seq: a High-Throughput Method to Map Viral ''cis''- and ''trans''-Acting Elements". mBio.